The role of lamivudine versus entecavir in prevention of HCC in patients with hepatitis B virus-related cirrhosis
2013
Methods We included 36 patients with hepatitis B virus related cirrhosis. Since February 2008 until now, 45% (16 patients) were treated with lamivudine and 55% (20 patients) with entecavir. The evaluation was performed every 3-4 months by clinical exam, biochemical and serological tests, and abdominal ultrasonography for all patients. Upper endoscopy, computed tomography scanning or magnetic resonance imaging were done in selective cases.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
12
Citations
NaN
KQI